Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.

ABSTRACT: The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in BRCA1/2 mutation carriers. Identification of additional biomarkers can help expand the population of patients most likely to benefit from olaparib treatment. To identify candidate markers of olaparib response we analyzed genomic and in vitro olaparib response data from two independent groups of cancer cell lines. Using pan-cancer cell lines (n = 896) from the Genomics of Drug Sensitivity in Cancer database, we applied linear regression methods to identify statistically significant gene predictors of olaparib response based on mRNA expression. We then analyzed whole exome sequencing and mRNA gene expression data from our collection of 18

SUBMITTER: Amuzu S 

PROVIDER: S-EPMC7998846 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature